Global Cardiac Biomarkers Market Size research report 2022 offers in-depth assessment of revenue growth, market definition, segmentation, industry potential, influential trends for understanding the future outlook and current prospects for the market.
The global cardiac biomarkers market size stood at USD 13.15 billion in 2019 and is projected to reach USD 26.33 billion by 2027, exhibiting a CAGR of 11.2% during the forecast period.
Drivers & Restraints
The burden of cardiovascular diseases (CVDs) is rising globally, owing to numerous factors such as smoking, diabetes, obesity, and lifestyle changes. According to the National Centre for Health Statistics, coronary artery diseases (CAD) account for 1 in 4 deaths in the U.S. annually. According to, Centers for Disease Control and Prevention, around 1.5 million cases of myocardial infarctions are registered annually in the United States. Additionally, according to Patient Platform Limited, around 103,000 people in the United Kingdom suffer from myocardial infarction each year. Rising prevalence of cardiovascular disorders is one the major factor anticipated to drive the market growth during the forecast period.
This study provides information about the sales and revenue during the historic and forecasted period of (2022 to 2028). Understanding the segments helps in identifying the importance of different factors that aid market growth. Estimations about the CAGR value for specific forecast period, market drivers, market restraints, and competitive strategies are assessed in this Cardiac Biomarkers Market report.
This report focuses on Cardiac Biomarkers Market volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Cardiac Biomarkers Market market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East and Africa.
Cardiac biomarkers were evaluated by the ARCHITECT STAT (Abbott Diagnostics) and ACCESS (Beckman Coulter) high-sensitivity troponin I assays, the Elecsys Troponin T Gen5 STAT assay (Roche Diagnostic), and the Elecsys ProBNP II assay (Roche Diagnostics).
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
An Overview of the Impact of COVID-19 on this Market:
The advancement of COVID-19 has conveyed the world to a stop. We fathom that this prosperity crisis amazingly influences associations across ventures. Nevertheless, everything fortunate or unfortunate should reach a conclusion. There are a couple of organizations that are fighting and some are thriving. By and large, essentially every region is relied upon to be impacted by the pandemic.
We are advancing incessant endeavors to help your business support and create during COVID-19 pandemics. Considering our experience and expertise, we will offer you an impact examination of Covid episode across ventures to help you with preparing for what’s to come.
The rising number of patients suffering from acute coronary syndrome (ACS) is among the key factors stimulating the cardiac biomarkers market. Apart from this, the inflating awareness among patients and healthcare providers about the importance of early diagnosis of several cardiovascular diseases (CVDs) is also propelling the global market.
Besides this, the increasing number of private and public organizations that are investing in research and development (R&D) activities to develop advanced technologies in the field of biomarkers is further fueling the market growth. Additionally, the expanding demand for high accuracy and rapid results offered by biomarker testing and the elevating availability of affordable cardiac point-of-care testing are expected to positively influence the cardiac biomarkers market over the forecasted period.
Cardiovascular Ultrasound System Overview
Cardiovascular ultrasounds, also known as echocardiograms, use ultrasound imaging to create an image of the heart. It is non-invasive and aids in diagnosing and managing potentially fatal cardiovascular diseases such as heart attack, congenital heart disease, coronary artery disease, and others.
Cardiovascular ultrasonography is a painless diagnostic that uses sound waves to create moving images of the heart. Cardiovascular ultrasonography is another name for echocardiography. It can help detect blood clots in the heart. Furthermore, the cardiovascular ultrasonography system evaluates the health of the heart muscle. The three types of cardiovascular ultrasonography currently available are transthoracic echocardiography, transesophageal echocardiogram, and stress echocardiogram.
“BNP is marker that varies dramatically depending on the patient’s fluid status. A more stable marker such as suPAR that is linked to the pathophysiology of heart failure could be more useful in identifying patients at higher, long-term risk of disease progression or death.”
Key players covered in the global Cardiac Biomarkers Market research report:
- F. Hoffmann-La Roche AG
- Siemens AG
- Creative Diagnostics
- Beckman Coulter, Inc.
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific Inc.
- bioMérieux SA
Market Share Analysis:
The cardiovascular ultrasound system market is expected to show positive growth due to several factors, including an increase in the geriatric population, an increase in the incidence of cardiovascular diseases, an increase in sedentary lifestyles, and an increase in regulatory approvals for the cardiovascular ultrasound system.
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
However, with the mass vaccination of the population, the relaxation of lockdowns, the resumption of hospital visits, and the availability of staff for performing diagnosis procedures, the cardiovascular ultrasound system market has regained momentum and is expected to grow further during the forecast period.
A growing body of research links suPAR and poor outcomes for an array of conditions, from coronary artery disease to cancer and kidney dysfunction. The common pathway of disease in these conditions is a persistent activation of the immune system, which is reflected in high suPAR levels, says Hayek, whose research focuses on understanding the link between inflammation, cardiovascular and kidney diseases.
- Natural substance providers
- Administrative bodies, including government organizations and NGO
- Business innovative work (RandD) establishments
- Merchants and exporters
- Government associations, research associations, and counseling firms
- Exchange affiliations and industry bodies
- End-use enterprises
Major Table of Contents for Cardiac Biomarkers Market Research Report:
- Executive Summary
- Market Dynamics
- Key Market Growth Insights
- Global Market Analysis, Insights and Forecast, 2017-2028
- North America Market Analysis, Insights and Forecast, 2017-2028
- Europe Market Analysis, Insights and Forecast, 2017-2028
- Asia Pacific Market Analysis, Insights and Forecast, 2017-2028
- The Middle East and Africa Market Analysis, Insights and Forecast, 2017-2028
- Latin America Market Analysis, Insights and Forecast, 2017-2028
- Competitive Landscape
- Global Cardiac Biomarkers Market Revenue Growth, Industry Share Analysis, By Key Players, 2021
- Company Profiles
Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune – 411045, Maharashtra, India.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245